Aclaris Therapeutics (ACRS) Income from Continuing Operations (2014 - 2026)
Aclaris Therapeutics' (ACRS) quarterly Income from Continuing Operations came in at 37461000.0 in Q1 2026, down 102.61% year-on-year from 1433988465.84 in Q1 2025, and down 19.61% quarter-over-quarter from 31318000.0 in Q4 2025.
Aclaris Therapeutics (ACRS) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 37461000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 102.61% year-over-year to 37461000.0 in Q1 2026; TTM through Mar 2026 was 106836000.0, a 27.77% increase from a year earlier, with the FY2025 full-year figure at 272973000.0, down 106.7% from the prior year.
- Income from Continuing Operations retreated to 37461000.0 in Q1 2026 per ACRS's latest filing, from 31318000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1872000.0 in Q4 2023 and bottomed at 213199000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 32165000.0 (2022), against an average of 41168352.94.
- Across the five-year window, Income from Continuing Operations jumped 99.12% in 2023 and sank 5684.72% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 213199000.0 in 2022, then soared by 99.12% to 1872000.0 in 2023, then sank by 5684.72% to 108290000.0 in 2024, then surged by 71.08% to 31318000.0 in 2025, then fell by 19.61% to 37461000.0 in 2026.
- Per Business Quant, the three latest ACRS Income from Continuing Operations figures stand at 37461000.0 (Q1 2026), 31318000.0 (Q4 2025), and 19191000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Aclaris Therapeutics | 672.39 Mn | 672.39 Mn | 1.60 Mn | -37.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.46 Mn |
| Dec 31, 2025 | -31.32 Mn |
| Sep 30, 2025 | -19.19 Mn |
| Jun 30, 2025 | -18.87 Mn |
| Mar 31, 2025 | -18.49 Mn |
| Dec 31, 2024 | -108.29 Mn |
| Sep 30, 2024 | -9.66 Mn |
| Jun 30, 2024 | -11.47 Mn |
| Mar 31, 2024 | -17.43 Mn |
| Dec 31, 2023 | -1.87 Mn |
| Sep 30, 2023 | -32.94 Mn |
| Jun 30, 2023 | -39.00 Mn |
| Mar 31, 2023 | -34.12 Mn |
| Dec 31, 2022 | -213.20 Mn |
| Sep 30, 2022 | -36.39 Mn |
| Jun 30, 2022 | -32.17 Mn |
| Mar 31, 2022 | -38.01 Mn |
| Dec 31, 2021 | -184.94 Mn |
| Sep 30, 2021 | -38.44 Mn |
| Jun 30, 2021 | -35.52 Mn |